P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China

Xu, Chong-Rui; Zhang, Y.; Liu, D.; Shen, Ronglai; Razavi, Pedram; Liu, S.; Sun, Huihui; Offin, Michael; Drilon, Alexander; Rudin, Charles M.; Arcila, Maria E.; Wu, Yi‐Long; Li, B.

doi:10.1016/j.jtho.2018.08.655

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The co-occurring genomic spectrum of ERBB2ex20ins in our cohort of Chinese people had an overall strong concordance with the MSKCC cohort from the United States (R 2 = 0.74, p < 0.01). In a retrospective study collated two cohorts of patients with ERBB2 alteration from the MSKCC and Guangdong General Hospital, they also found great consistency with each other in the aspect of the prevalence and baseline clinical parameters of patients possessing ERBB2 mutation (34). These findings, on the one hand, can be supporting evidence for U.S.-China collaborations in clinical trials to accelerate new drug development for this infrequent mutation; on the one hand, highlight the robustness of our results.…”

Section: Discussionmentioning

confidence: 76%

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

et al. 2020

View full text Add to dashboard Cite

Background: Human epidermal growth factor receptor 2 (ERBB2, HER-2) exon 20 insertion (ERBB2ex20ins) remains a refractory oncogenic driver in lung cancer. So far there is limited data showing the co-occurring mutation background of ERBB2ex20ins in Chinese lung cancer and its relationship with response to afatinib. Patients and Methods: A total of 112 Chinese patients with ERBB2ex20ins identified by next-generation sequencing from 17 hospitals were enrolled. The clinical outcomes of 18 patients receiving afatinib treatment were collected. Results: Among the 112 patients, insertion-site subtypes comprised of A775ins (71%; 79/112), G776indel (17%; 19/112), and P780ins (12%; 14/112). There were 66.1% (74/112) of patients carrying TP53 co-mutation and FOXA1 was the most prevalent co-amplified gene (5.5%, 3/55). The co-occurring genomic feature was similar among three insertional-site subtypes and had an overall strong concordance with the western population from the MSKCC cohort (R 2 = 0.74, P < 0.01). For the prognosis, patients with co-occurring mutation in cell-cycle pathway especially TP53 showed shorter OS than patients without [median OS: 14.5 m (95% CI:12.7-16.3 m) vs. 30.3 m (95% CI: not reached), p = 0.04], while the OS was comparable among three subtypes. For Yuan et al. ERBB2 and Afatinib the response to afatinib, ERBB2ex20ins as a subclonal variant was an independent factor relating to shorter PFS [median PFS: 1.2 m (95% CI: 0.8-1.6 m) vs. 4.3 m (95% CI: 3.3-5.3 m), p < 0.05]. Conclusion: Our data revealed co-occurring TP53 represent an unfavorable prognosis of patients with ERBB2ex20ins, emphasizing the more valuable role of the co-mutation patterns than insertion-site subtypes in predicting prognosis of this group of patients. Moreover, the clonality status of ERBB2ex20ins was identified as a potential indicator for response to afatinib.

show abstract

Section: Discussionmentioning

confidence: 76%

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, whether this technique could detect the amplification of HER2 in NSCLC by plasma genotyping had not been discussed previously. Besides dPCR, next-generation sequencing (NGS) is also used to reveal HER2 alterations in NSCLC patients (16). However, compared with NGS, the validity of dPCR, and the feasibility of detecting in blood samples in NSCLC patients are still unclear.…”

Section: Introductionmentioning

confidence: 99%

Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer

Qi¹,

Xiong²,

Jiang³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China

Cited by 2 publications

References 0 publications

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

Blood digital polymerase chain reaction as a potential method to detect human epidermal growth factor receptor 2 amplification in non-small cell lung cancer

Contact Info

Product

Resources

About